BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 10/23 cls
Affymetrix Inc. (NASDAQ:AFFX) UBS Derik De Bruin Price target Neutral -24.8% $6.68
De Bruin lowered his target to $9.50 from $10.50 after Affymetrix reported 3Q09 revenues of $78M, missing the Street's estimate of $81M and losing more per share than anticipated.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy 4.2% $47.97
Cowen Eric Schmidt Other Overweight
Piper Jaffray Edward Tenthoff Price target Overweight
Aschoff raised his target to $55 from $46 after Alexion guided for FY09 EPS of $1.15-1.18, up from the previous range of $1.01-1.06. He now expects FY09 sales of Soliris eculizumab to be $386M, up from $377M. The humanized mAb targeting complement C5 is approved in the U.S., EU, Canada and Australia to treat paroxysmal nocturnal hemoglobinuria (PNH).
Schmidt raised...

Read the full 909 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >